Compare ASE Technology Holding Co Ltd (ASX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ASE Technology Holding Co Ltd vs TG Therapeutics Inc — how do they compare? ASE Technology Holding Co Ltd trades at $39.82 (market cap $87.94B), while TG Therapeutics Inc trades at $55.76 (market cap $8.41B). The key difference: ASE Technology Holding Co Ltd is far larger — about 10.5× TG Therapeutics Inc's market cap, and ASE Technology Holding Co Ltd pays a 1.03% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ASX | TGTX | |
|---|---|---|
Market Cap | $87.94B | $8.41B |
Sector | Technology | Health |
52-Week High | $45.12 | $59.06 |
52-Week Low | $9.50 | $26.39 |
Enterprise Value | $92.38B | $8.65B |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASE Technology Holding (ASX) trades at $40.56, down 4.92% over 24 hours, with a neutral technical signal. The company shows strong earnings momentum with three consecutive quarterly beats and robust cash flow growth. Revenue reached $645.39B in 2025 with net income of $40.02B, while analyst sentiment remains positive with 80% buy ratings. Recent news highlights AI-driven packaging demand and LEAP business growth exceeding $3.5B in 2026 revenue outlook.
The stock presents growth potential from AI infrastructure demand and margin expansion, though elevated P/E ratio of 63.65 suggests premium valuation. Key risks include semiconductor cycle volatility and execution challenges in scaling advanced packaging capacity. Institutional ownership trends and positive earnings revisions support the bullish case, but investors should monitor competitive pressures in the semiconductor packaging sector.
TG Therapeutics (TGTX) trades at $55.01, down 3.69% today, with a bullish technical signal from moving averages and a consensus analyst rating of 'Buy' from 11 of 13 analysts. The company reported strong revenue growth to $616.29 million in 2025 and a net income of $447.18 million, though recent quarterly EPS misses and negative operating cash flow of -$24.77 million highlight volatility. Positive news includes Phase II trials for Briumvi in schizophrenia and Phase I success in myasthenia gravis, driving investor optimism.
Outlook: TGTX offers growth potential through pipeline expansion and robust sales guidance, but faces risks from clinical trial outcomes, cash flow challenges, and high valuation multiples. The stock's 70% year-to-date gain reflects high expectations, requiring careful monitoring of execution against earnings forecasts and regulatory milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ASE Technology Holding Co Ltd
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
